1. Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy following mRNA SARS-CoV-2 Vaccination
- Author
-
Marta Rodrigues de Carvalho, Myrian Mathildes Sá de Deus Rocha, Vinícius Alves Bezerra, Maciel Eduardo de Pontes, Maria Cristina del Negro, Julio Salgado Antunes, Vinícius Viana Abreu Montanaro, and Rubens Nelson Morato Fernandez
- Subjects
Neurology. Diseases of the nervous system ,RC346-429 - Abstract
The new coronavirus (COVID-19) pandemic has resulted in the unprecedented production of vaccines. In this context, the possible adverse effects remain to be identified and reported. In this article, we report the case of a young female patient who developed anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMG-CoA) immune-mediated necrotizing myositis (IMNM) after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine. The diagnosis of probable post-vaccination IMNM was made due to the absence of other factors that may have led to the development of autoantibodies (medicines; e.g., statins, drugs) and the temporal relationship between exposure and event. This case report is the first to suggest that a COVID-19 vaccine may trigger anti-HMG-CoA reductase necrotizing myopathy.
- Published
- 2023
- Full Text
- View/download PDF